| 证券代码 | PRAH.O |
| 证券名称 | PRA Health Sciences Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2014-11-13 |
| 首发价格(元) | 18 USD |
| 首发数量(股) | 16976744 |
| 首发募资额(元) | 305,581,392.00 USD |
| 首发主承销商 | Citigroup Global Markets Inc,Jefferies LLC,KKR Capital Markets L |
| 货币单位 | USD |
| 公司名称 | PRA Health Sciences, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 4130 ParkLake Avenue, Suite 400, Raleigh, New Caledonia, USA |
| 成立日期 | 2013-06 |
| 董事会主席 | Colin Shannon |
| 公司属地 | United States 美国 |
| 公司网址 | www.prahs.com |
| 电话 | +1 (919) 786-8200 |
| 传真 | +1 (919) 786-8201 |
| 公司简介 | PRA Health Sciences, Inc. is one of the world’s leading global contract research organizations, or CROs, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It believes it is one of a select group of CROs with the expertise and capability to conduct clinical trials across all major therapeutic areas on a global basis. It has therapeutic expertise in areas that are among the largest in pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. It believes it provides its clients with one of the most flexible clinical development service offerings, which includes both traditional, project based Phase I through Phase IV services as well as embedded and functional outsourcing services. It believes it further differentiates itself from its competitors through its investments in medical informatics and clinical technologies designed to enhance efficiencies, improve study predictability and provide better transparency for its clients throughout their clinical development processes. It is one of the largest CROs in the world by revenue, focused on executing clinical trials on a global basis. Its global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and over 13,000 employees worldwide. Since 2000, it has participated in approximately 3,500 clinical trials worldwide, it has worked on marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to U.S. Food and Drug Administration, or FDA, or international regulatory approval of more than 70 drugs. |